BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (August 2016)
28 slides from BioSpecifics Technologies's investor presentation, Aug 15, 2016
Slide 1: Innovators in the development & commercialization of injectable collagenase
) a ad \ a? < om Innovators in the development & commercialization of _ INJECTABLE COLLAGENASE c “~~ = We BioSpecifics August 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding
Slide 3: Originator of collagenase-based therapies
Originator of collagenase based-therapies Profitable biopharma company with lean corporate structure and stock buy-back program Receives revenues from XIAFLEX® milestones, royalties on net sales, mark-up on COGS and sublicense income by partner Endo o 00640 6 Future revenue growth opportunities from
Slide 4: Unlocking Vast Potential of XIAFLEX
Unlocking Vast Potential of XIAFLEX XIAFLEX: First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications Drive R&D in new indications to early proof-of-conc
Slide 5: Marketed XIAFLEX Indications
Marketed XIAFLEX Indications: First, Effective Nonsurgical Treatment Options
Slide 6: Dupuytren's Contracture
XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Pre-treatment: Post-treatment: ~ Source: Endo Interna
Slide 7: Commercial Highlights for Dupuytren's Contracture
Commercial Highlights for Dupuytren’s Contracture ~6,530 demand vials in 2Q16 in U.S. ~1.2 vials/patient Statistically significant results from Phase 2a study in Dupuytren’s nodules Nodules are far more prevalent than contractures Endo to begin registration trial in 4Q16* Updated U.S. label includin
Slide 8: Peyronie's Disease
XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self
Slide 9: Commercial Highlights for Peyronie's Disease
Commercial Highlights for Peyronie’s Disease ~8,197 demand vials in 2Q16 ~4.5 vials/patient In May 2015: The American Urological Association presented first ever treatment guidelines for PD, recommending the use of XIAFLEX® in combination with modeling in patients with stable disease Positive data s
Slide 10: XIAFLEX 2Q16 Sales and Future Growth Initiatives
XIAFLEX 2Q16 Sales and Future Growth Initiatives 2Q16 U.S. net revenues were $42.4 million and worldwide net revenues were $45.2 million FUTURE GROWTH INITIATIVES: Broaden physician base with improved targeting to reach the most appropriate physicians Direct to consumer campaign traction Dupuytren’s
Slide 11: Pipeline Indications
XIAFLEX® Pipeline Indications
Slide 12: Pipeline Programs
XIAFLEX® Pipeline Programs Future Revenue-Generating Opportunities Phase 2b initiated in Cellulite endo es 1016 Adhesive Initiate Phase 2b in Capsulitis endo —— egies Phase 2 top-line Human results reported in lipoma SS June 2016 by BSTC, Endo July opt-in % Endo has license Fae 1 for further Hpema d
Slide 13: Adhesive Capsulitis
XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical thera
Slide 14: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis
Phase 2b Study Results of XIAFLEX' in Adhesive Capsulitis/Frozen Shoulder Syndrome Phase 2a Results 321 patient double-blind, placebo-controlled study @ evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder 30 Primary endpoint: change in degrees from baseline
Slide 15: Cellulite: Phase 2b Study Initiated in February
XIAFLEX® for Cellulite Phase 2b Study Initiated in February 201 Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affects ~85-98% of post-pubertal females Phase 2b Study Design Enrolling 350 women (18+ years) Up to 3 treatment sessions o
Slide 16: Cellulite: Positive Top-line Data from Phase 2a Study
XIAFLEX® for Cellulite Positive Top-line Data from Phase 2a Study Top-line data from Phase 2a study: 150 women received up to three treatment sessions of drug or placebo according to randomization (5 high-dose (0.84mg): 5 mid (0.48mg): 5 low (0.06mg): 3 placebo) Mid and high level XIAFLEX® doses dem
Slide 17: Human Lipomas
XIAFLEX® for Human Lipomas Endo Opted-in in July 2016 Triggering $750,000 Payment Potential to be Only FDA-Approved Pharmaceutical Therapy . Market Opportunity Phase 2 Trial Design Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapies a
Slide 18: Positive Top-Line Phase 2 Study Results
Positive Top-Line Phase 2 Study Results Single 0.58 mg Injection of CCH Primary endpoint: 81.3% reduction in visible surface area for CCH vs. 2.1% increase for placebo; 83.4% difference in favor of CCH (p<0.0001) 89.5% responder rate (showed a 250% decrease in lipoma visible surface area relative to
Slide 19: Lipomas in Canines
XIAFLEX® for Lipomas in Canines Potential to be Only FDA Approved Nonsurgical Therapy Key Complications Market Opportunity Chien-80- Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affected in
Slide 20: Uterine Fibroids
XIAFLEX® for Uterine Fibroids Clinical Trial to Begin in 2H16 Benign tumors in the reproductive tract that contain large amounts of collagen Definition & Key Cause pelvic discomfort and pain, decreased fertility, pregnancy Complications complications, increased rate of miscarriage, heavy menstrual b
Slide 21: Lateral Hip Fat
XIAFLEX® for Lateral Hip Fat Phase 2 Trial to Begin in 4Q16* Definition & Complications Similar prevalence to cellulite Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise an
Slide 22: Plantar Fibromatosis
XIAFLEX® for Plantar Fibromatosis Phase 2 Trial to Begin in 3Q16* Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease
Slide 23: Additional Promising Unlicensed Indications
Additional Promising Unlicensed Indications Capsular Contracture, Breast: Post-surgical complication that can deform the breast and cause pain ~15% of breast augmentation / reconstructive surgery patients Hypertrophic Scars & Keloids: Scars that form on the skin at site of injury ~600,000 scar and ~
Slide 24: Endo Partnership for Development and Commercialization of XIAFLEX
Endo Partnership for Development and Commercialization of XIAFLEX® $94.7M received in licensing, sublicensing, milestone, >$94.7M Received COGS, and royalty payments as of June 30, 2016 as of June 30, 2016 BioSpecifics to receive opt-in payment of $750,000 for human lipoma indication in 3Q16 Low dou
Slide 25: Strong IP Portfolio
Strong IP Portfolio Long-term patent protection for CCH Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Patents and Patent Applications Owned, co
Slide 26: Consistently Profitable Annually
Consistently Profitable Annually Financial Highlights (unaudited) For the six months ended 06/30/16 06/30/15 7 Cash and equivalents, and investments $45,836,222 $37,081,958 Income Statement Revenues $12,748,147 $10,321,429 Other income 151,224 36,835 Costs and expenses (4,759,393) (4,094,588) Provis
Slide 27: Anticipated Upcoming Pipeline Milestones
Anticipated Upcoming Pipeline Milestones Uterine Fibroids* C1 Initiate clinical trial in 2H16 Adhesive Capsulitis C1 Initiate Phase 2b trial in 3Q16** Cellulite O Announce top-line data from recently initiated Phase 2b trial Lateral Hip Fat C1 Initiate Phase 2 trial in 4Q16** Plantar Fibromatosis C1
Slide 28: Innovators in the development & commercialization of injectable collagenase
f ¢ \ a? < = Innovators in the development & commercialization of INJECTABLE COLLAGENASE BioSpecifics August 2016
BioSpecifics Technologies — Investor Presentation (August 2016) on 6ix